British American Tobac (BTI) Earnings Date & Reports

Key Takeaways

• British American Tobacco (BTI) reported first-half (H1) 2026 adjusted diluted earnings per share (EPS) of $2.25, beating the consensus estimate of $2.14.
• Revenue reached $16.46 billion, slightly ahead of the $16.42 billion expectation and up 5.16% year over year.
• New Categories revenue accelerated 18%, led by Modern Oral growth of 66%, as smokeless products rose to 19.8% of group revenue.
• Full-year adjusted EPS guidance was upgraded to the middle of the 5%–8% growth range, though revenue and operating profit are expected at the lower end of the algorithm.
• Combustible volume declined 4.7%, but combustible revenue still grew 2.1% on a 6.8% price/mix contribution.
• For more details on the company, explore its Major News, Today's Price Move, Price Targets, and Forecast pages.
• Looking for automated ideas? Discover Trending AI Robots to see data-driven trading strategies in action.

Earnings Context and Why It Matters

British American Tobacco reports on a half-yearly basis rather than standard calendar quarters, making its H1 2026 results a key checkpoint on the company's transition from traditional cigarettes toward smokeless, reduced-risk products. This report matters because it tests whether the New Categories segment—especially Modern Oral and Vapour—can offset persistent combustible volume declines while still protecting margins and cash generation. Investors also watch closely for progress on the Fit2Win transformation program, deleveraging toward the 2.0–2.5x target range, and the sustainability of shareholder returns through dividends and buybacks.

Reported Results

For the first half of 2026, British American Tobacco delivered adjusted diluted EPS of $2.25, exceeding the $2.14 consensus estimate. Revenue came in at $16.46 billion, modestly above the $16.42 billion analysts expected and up 5.16% year over year. On a constant-currency basis, group revenue rose 2.9%, adjusted gross profit increased 3.8%, adjusted profit from operations grew 3.5%, and adjusted diluted EPS advanced 7.9%.

New Categories was the standout, with revenue up 18%, including a 66% surge in Modern Oral and 5.3% growth in Vapour. Smokeless products now represent 19.8% of group revenue, up 160 basis points year over year, with the company adding 4.1 million smokeless consumers over the trailing 12 months to reach 35 million. In the United States, total revenue rose 8.5% and adjusted operating profit climbed 10.1%, supported by strong momentum in Velo Plus and Vuse. Combustible revenue grew 2.1% despite a 4.7% volume decline, reflecting a 6.8% price/mix contribution. Group operating margin expanded 30 basis points to 43.7%.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending stocks, and breakout candidates far more efficiently than manual screening. Explore the AI Screener to refine your own watchlist.

Market Reaction and Investor Sentiment

Sentiment around the H1 2026 release leaned positive, driven by accelerating New Categories momentum, improving margins, and an upgraded full-year EPS outlook. Management framed the results as evidence that the company is progressing toward its midterm growth algorithm, even as combustible volume declines and regional pressures persist. Notably, the company flagged near-term headwinds, including declines in Heated Products and Vapour revenues in some regions, profit pressure in the Asia-Pacific, Middle East, and Africa (APMEA) segment, and a market-specific shock from a Brazil excise change. These factors, alongside transactional foreign-exchange (FX) headwinds, tempered the positive narrative and contributed to expectations for a second-half-weighted recovery.

Forward Outlook and Key Factors to Monitor

Management guided toward a second-half-weighted improvement, with adjusted profit from operations expected to accelerate in the second half and full-year adjusted EPS now anticipated toward the middle of the 5%–8% range. Revenue and operating profit are projected at the lower end of the algorithm after absorbing roughly 1% of transactional FX headwinds.

Investors should monitor the trajectory of New Categories, where management expects mid-teens revenue growth in the second half following an 18% first-half increase and 66% growth in Modern Oral. The Fit2Win transformation remains central to the margin story, with annualized savings now targeted at £700 million by 2028 and £500 million by 2027. Cash generation, the £1.3 billion 2026 share buyback, and the progressive dividend also remain focal points.

Key risks to watch include combustible volume declines, regulatory and illicit-market pressures, and regional performance in APMEA. The next major checkpoint is the company's full-year 2026 results, which management has scheduled for early 2027, when investors will assess whether the recovery materialized as guided.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations